Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases

Journal of Musculoskeletal Neuronal Interactions

Volumn 7, Issue 1, 2007, Pages 2-8

  Francis, Marion D ^a,b   Valent, D J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b NONE   (United States)

Author keywords

Bisphosphonates; Etidronate; Hydroxyapatite; Osteoporosis; Pyrophosphate

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; HYDROXYAPATITE; HYDROXYPROLINE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RADIOISOTOPE; RISEDRONIC ACID; TECHNETIUM 99M; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BINDING AFFINITY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL RESEARCH; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG ADSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERCALCEMIA; NONHUMAN; OSSIFYING MYOSITIS; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PHYSICAL CHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; SOFT TISSUE CALCIFICATION; TREATMENT DURATION;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 34248369003     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Von Baeyer H, Hofmann KS. Acetodiphosphoriga sauer. Ber 1897; 30:1973.
2. Blaser B, Worms KH. Application of organic acylation products of phosphorus or their derivatives as complexing agents for metal ions. Henkel & Cie G.m.b.H., Germany 1,082,235, 1960; May 25.
3. Francis MD, Gray JA, Griebstein WJ. The formation and influence of surface phases on calcium phosphate solids. Adv Oral Biol 1968; 3:83-120.
4. Francis MD. Oral compositions for caries prophylaxis. Procter and Gamble Co., Cincinnati, Ohio, USA 3,235,459, 1966, Feb. 15.
5. Francis MD, Briner WW. The effect of phosphonates on dental enamel in vitro and calculus formation in vivo. Calcif Tissue Res 1973; 11:1-9.
6. Francis MD. The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 1969; 3:151-162.
7. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165:1262-1264.
8. Jones AG, Francis MD, Davis MA. Bone scanning: radionuclidic reaction mechanisms. Semin Nucl Med 1976; 6:3-18.
9. Francis MD, Horn PA, Tofe AJ. Controversial mechanism of technetium -99m deposition on bone. J Nucl Med 1981; 22:72.
10. Francis MD, Flora L, King WR. The effect of disodium ethane-1-hydroxy-1,1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tissue Res 1972; 9:109-121.
11. Francis MD, Martodam RR. In: Hilderbrand RL (ed) The Role of Phosphonates in Living Systems. CRC Press Inc., Boca Raton, FL; 1983:55-96.
12. Briner WW, Francis MD. In vitro and in vivo evaluation of anti-calculus agents. Calcif Tissue Res 1973; 11:10-22.
13. Wang Q, Finsy R, Xu H, Li X. On the critical radius in generalized Ostwald ripening. J Zhejiang Univ Sci B 2005; 6:705-707.
14. Surfaces of Solids. In: Adamson AW, Gast AP (eds) Physical Chemistry of Surfaces. Wiley-Interscience Publications, John Wiley & Sons Inc., New York; 1997:VII: 262-263; X:347-348.
15. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165:1264-1266.
16. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. Diphosphonates in the treatment of myositis ossificans. Lancet 1969; 2:845.
17. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet 1971; 1:945-947.
18. Altman RD, Johnston CC, Khari MRA, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis ossificans). N Engl J Med 1973; 289:1379-1384.
19. Finerman GAM, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Rel Res 1981; 3:337-342.
20. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E. Treatment of hypercalcemia of malignancy with intravenous etidronate: a controlled, multicenter study. Arch Intern Med 1991; 151:471-476.
21. Chilton HM, Francis MD, Thrall JH. In: Swanson DP, Chilton HM, Thrall JH (eds) Pharmaceuticals in Medical Imaging. McMillan Publishing Company, New York, NY; 1990:537-563.
22. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Roa MB, Steiger P, Richmond B, Chesnut CH. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl J Med 1990; 323:73-79.
23. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 282:1344-1352.
24. Boonen S, Delmas PD, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES. Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study. Osteoporos Int 2006; 17(Suppl.2):S230-S231.
25. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. Effects of risedronate treatment on corticosteroid therapy. Calcif Tissue Int 2000; 67:277-285.
26. Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JVS, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003; 9:2394-2399.